Spark Therapeutics Stock
Price
Target price
-
-
-
-
-
-
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Pros and Cons of Spark Therapeutics in the next few years
Pros
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
M***** P*******
Cons
?
S********** s********
?
B****
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Spark Therapeutics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Spark Therapeutics | - | - | - | - | - | - | - |
| Ligand Pharmaceuticals | -2.360% | -0.781% | -9.286% | 117.094% | 53.012% | 313.008% | 171.194% |
| United Therapeutics | -1.550% | 3.809% | -3.937% | 79.784% | 9.057% | 115.741% | 156.044% |
| Ionis Pharmaceuticals Inc. | 0.290% | 8.773% | -33.915% | 39.931% | -28.119% | 35.356% | 47.985% |
News
Envista Q2 Earnings Call Highlights
Key Points
- Interested in Envista Holdings Corporation? Here are five stocks we like better.
- Strong second-quarter performance: Envista reported $731 million in sales, up just over 7% year over
Omada Health Q2 Earnings Call Highlights
Omada Health (NASDAQ:OMDA) reported record second-quarter results for 2026, citing broad-based growth across its cardiometabolic programs, expanding channel partnerships and lower costs to serve
Cirrus Logic Q1 Earnings Call Highlights
Key Points
- Interested in Cirrus Logic, Inc.? Here are five stocks we like better.
- Record quarterly performance: Cirrus Logic reported fiscal Q1 revenue of $460 million, up 13% year over year